Australian institution to invest $2.7 million in OSL
Filed with ASX · · 2 pages · English
Summary by 6ix AI
OncoSil Medical Ltd has announced a commitment for an investment from an Australian institutional investor to raise funds through a placement. The placement will generate significant capital to support the commercialization and regulatory accreditation of the OncoSil device for pancreatic cancer treatment. The investment will also aid in manufacturing optimization and fund clinical trials to expand the device's approval. Following the placement, the institutional investor will hold a notable percentage of the company's issued shares.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from OncoSil Medical
- $5.3 million raised under Entitlement Offer
- 1st Study in Man Increases Pancreatic Tumor Vascularity
- First patient treated with OncoSil device in Turkiye
- First patient treated in the UK for the TRIPP-FXX study
- First Austria-based treatments utilising the OncoSil device
Later from OncoSil Medical
- Successful Treatment with OncoSil Device in Turkiye
- Appendix 4E Preliminary Financial Report
- G-BA Approval received for OncoSil Device
- OSL completes $7 M Placement and announces $1 M SPP
- Prospectus 2024 Share Purchase Plan (SPP) Offer
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical